



Endometrial Receptivity Testing - ERA

Patient Information

Summary of Endometrial Receptivity Testing

IVF/ICSI involves the creation of embryos in the laboratory and their subsequent transfer to a receptive uterus, hopefully leading to pregnancy. Recent research has identified that for approximately 1 in 4 patients there is a discrepancy between the stage of embryo development and the receptivity of the uterus. Where a discrepancy is detected, embryos can be frozen and replaced at a later date when the uterus is in a more receptive state.

What is the Endometrial Receptivity Array Test?

This genetic test is a revolutionary new method of assessing when the endometrium (the membrane that lines the inside of your uterus) is receptive to the embryo, in order to give a personalised embryo transfer. This technique helps evaluate your endometrial receptivity from a molecular perspective and analyses sequencing expression of 236 genes involved in the endometrial receptivity.

When is it recommended and why?

Your endometrium is receptive when it is ready for the embryo implantation. This occurs around days 19-21 in each menstrual cycle of a fertile woman. This period of receptivity is called the window of implantation. Until recently there has been no way of accurately assessing whether the endometrium is at its most receptive.

This technique may be particularly useful for patients with repeated implantation failure. A displaced window of implantation is detected in approximately 25% of these patients. This analysis helps determine the personalised window of implantation, enabling personalized embryo transfer (pET) to be performed on the basis of these results.

What is the process?

To perform this analysis, it is necessary to take an endometrial biopsy from women in their natural cycle or hormone replacement therapy cycles, at a time corresponding to the phase of endometrial receptivity. That is, in the natural cycle, seven (7) days after the LH (luteinizing hormone) surge OR after five (5) full days of progesterone supplementation in Hormone replacement therapy (HRT) cycles. After the biopsy is taken it is immediately introduced into a tube which contains a fluid that facilitates the preservation of the tissue.

What are the advantages of ERA?

The receptivity of the endometrium is a crucial factor in determining the success of IVF treatment. This test indicates the window of implantation, increasing your chances of successful embryo transfer and achieving high success rates to our patients.

This test has shown not to discriminate between fertile and infertile patients, and it does not guarantee a successful outcome after personalised embryo transfer (pET).

<https://www.hfea.gov.uk/treatments/treatment-add-ons/endometrial-receptivity-testing/>



Address

BCRM - Bristol Centre for Reproductive Medicine
135 Aztec West
Almondsbury
Bristol
BS32 4UB



Telephone

0117 259 1159



Email

Contact@BCRM.clinic

